Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-FAPI-46 PET for staging and progression in transthyretin cardiac amyloidosis
2025-523616-36-00Phase 2Authorised
- Sponsor
- CHU de Nantes
- Start
- Sep 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 68Ga FAPI-46 in amyloidotic transthyretin cardiomyopathy (ATTR-CM), sponsored by CHU de Nantes. Planned start Sep 2026; status: authorised.
02
Drugs
68Ga FAPI-46
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on 2025-523616-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523616-36-00.